Peugeot's finance director Jean-Baptiste Chasseloup de Chatillon will replace Jérome Contamine as CFO at Sanofi upon his retirement at the end of September. Mr Chasseloup de Chatillon played a crucial part for PSA Group in reviving the business when it almost went bankrupt in 2012. Sanofi’s chief executive Olivier Brandicourt says Chasseloup de Chatillon will be of “great value” to the company after his involvement in the “impressive” turnaround of PSA Group.
“Peugeot's finance director Jean-Baptiste Chasseloup de Chatillon will replace Jérome Contamine as CFO at Sanofi upon his retirement at the end of September“
Sanofi is undergoing a restructure and making changes to its pipeline. Sales of its diabetes blockbuster Lantus (insulin glargine) fell by 18% to €911m in the first quarter of 2018, having reached a high of $8.5bn in 2014. It has transferred its anti-infectives unit to Evotec, and made two new acquisitions with Bioverativ, a haemophilia and blood disorder specialist, for $11.6bn and Ablynx for €3.9bn, which has its lead candidate and orphan drug caplacizumab for rare blood disorder acquired thrombotic thrombocytopenic purpura (aTTP).